Neoadjuvant Pembolizumab Improves Pathological Complete Response at Surgery in Asian Patients with Early TNBC
Subgroup of Asian patients with triple negative breast cancer demonstrates similar reponse as observed in patients overall in the KEYNOTE-522 study